The founder(s) and principals of HillMed have the vision of being able radically to change the diagnosis and treatment of neuromuscular disorder - including pelvic floor dysfunction - by leveraging their unique multidisciplinary expertise to create novel electromyographic solutions. The ongoing presence of chronic pelvic pain (for more than six months) changes that person's nervous system and/or brain occur in a process called sensitization. A complicating factor is that chronic pelvic pain can be difficult to diagnose: with overlapping clinical presentations and qualitative physical examination findings. In effect, current clinical diagnosis approaches of CPP, i.e., palpation and questionnaires - being subjective and non-quantitative - the lack of advanced diagnosis tools often leave majority of CPP patients undiagnosed and untreated for over that critical 6 months. To address thesel factors of delayed diagnosis and missed opportunity much earlier to address the problem, HillMed personnel are developing three medical devices to aid in the 1) diagnosis of chronic pelvic pain, 2) home care of chronic pelvic pain, and 3) therapeutic chemodenervation of pelvic floor. In 2022 a clinical trial was begun in collaboration with Baylor College of Medicine
